All In Biotech

Drug Trial Radar · NCT05285943

Use of Topical Olive Oil Cream for Prophylaxis Against Acute Radiodermatitis in Breast Cancer Patients

A Comparative Study Between Topical Betamethasone Cream or Topical Olive Oil Cream in Prophylaxis Against Acute Radiodermatitis in Breast Cancer Patients.

Last checked: Nov 19, 2026Latest source record: Feb 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 132 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

132

Actual

Start

Nov 4, 2021

Primary completion

Jan 31, 2024

Study completion Jan 31, 2024

Sponsor

Lead sponsor
Cairo UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 18, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to compare the prophylactic effect of topical betamethasone valerate cream and topical olive oil cream in the prevention of acute radiation dermatitis (ARD) in breast cancer patients treated with radiation. Betamethasone valerate, olive oil cream and the base cream will be compared in a randomized trial to evaluate and compare the development and degree of ARD grading according to Radiation Toxicity Grading (RTOG) skin toxicity score, percentage of patients with the maximum observed ARD grade for each arm of the study, percentage of patients with moist desquamation for each arm of the study, percentage of radiodermatitis-free patients at end of therapy (EOT=time point specifically at end of 2 weeks post radiation therapy). In addition, the patients' quality of life will be evaluated using Dermatology Life Quality Index (DLQI).

Conditions

  • Radiodermatitis; Acute

Interventions

  • Olive oil creamDrug

    Olive oil prepared in a base cream to be applied to irradiated areas.

  • Betamethasone Valerate CreamDrug

    Betamethasone valerate prepared in a base cream to be applied to irradiated areas.

  • Base CreamOther

    The base cream used for preparation of both the betamethasone valerate cream and olive cream will be used as a placebo control to be applied to irradiated areas.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Acute Radiation Dermatitis (ARD) gradingTime frame: T1=7 days after beginning treatment +/- 3 days; to T8=56 days after beginning treatment+/- 3 days}.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ain Shams University Hospitals

    Cairo, Egypt

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.